Evaluation of the Progression of Disease and Health-related Quality of Life in Patients With Pulmonary Hypertension: A Local Clinic-based Registry

All-cause mortality

Change in functional class (class I as the mildest to class IV as more severe) as measured by WHO functional class over times

Change in disease-specific health-related quality of life (QoL) as measured by EMPASIS-10 questionnaires which is an independent prognostic marker in patients with (I/D/H)PAH or CTD-PAH

pulmonary hypertension related mortality

Change in disease-specific health-related quality of life (QoL) as measured by Borg RPE scale which is an outcome measure scale used to gauge one's exercise intensity without the need to rely on physiological parameters

Change in disease-specific health-related quality of life (QoL) as measured by EQ-5D-5L which is for assessing patient health states for clinical and economic appraisal

Change in disease-specific health-related quality of life (QoL) as measured by mMRC which use to access stratifies severity of dyspnea in respiratory diseases, particularly COPD

Change in disease-specific health-related quality of life (QoL) as measured by PEmb-QoL which use to access QoL following PE

Change in physical parameters

Change in daily activity level

Change from baseline in log-transformed NT-proBNP level over time

Change in Six-minute walking test (6MWT)

Change in RVSP as echocardiographic parameters

Change in hemodynamic parameters

Change of PH specific medications number and dosage over time, including PDE5 inhibitor, Guanyl Cyclase stimulator, Endothelin Receptor antagonist, prostacyclin receptor agonist, and inhaled prostacyclin.

The costs of all services, medications and tests as estimated with reference to the Hong Kong Government Gazette 2020 and Hong Kong Hospital Authority Drug Formulary 2020

Change in physical parameters

Change in laboratory parameters